Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: Reporting extended results from phase III clinical trials
Authors:
- National Multiple Sclerosis Society Advisory Committee on Clinical Trials of New Agents in Multiple SclerosisNSNational Multiple Sclerosis Society Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis
- 1 July 1999
- journal article
- guideline
- Published by Wiley in Annals of Neurology
- Vol. 46 (1) , 132-134
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disabilityNeurology, 1998
- Improving the Quality of Reporting of Randomized Controlled TrialsJAMA, 1996
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Interferon beta‐lb in the treatment of multiple sclerosisNeurology, 1995
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- More Informative Abstracts RevisitedAnnals of Internal Medicine, 1990